Thus, we conducted the present study in order to investigate the possible difference in clinical outcomes between second-line osimertinib and ≥third-line treatment in advanced and recurrence EGFR-mutant NSCLC patients with acquired T790M mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.